The FDA issued a final rule that provides flexibility for nonanimal testing in preclinical drug development. The update clarifies that nonanimal methods can be used where appropriate for testing the safety of drugs and biologics intended for human use. This rule continues the agency’s shift away from mandatory animal testing requirements by making room for scientifically justified alternative approaches, potentially reducing barriers for developers that rely on modern in vitro systems and advanced methods. For biotech teams, the change can affect how preclinical study packages are designed and documented for IND submissions—especially for sponsors aiming to accelerate development or reduce reliance on animal studies. It also provides clearer regulatory language supporting nonanimal evidence strategies as acceptable components of safety assessments.